X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs GSK PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA GSK PHARMA ASTRAZENECA PHARMA/
GSK PHARMA
 
P/E (TTM) x 118.3 66.0 179.1% View Chart
P/BV x 16.8 10.6 158.8% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 ASTRAZENECA PHARMA   GSK PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
GSK PHARMA
Mar-17
ASTRAZENECA PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2853,838 33.5%   
Low Rs6342,637 24.0%   
Sales per share (Unadj.) Rs189.6354.2 53.5%  
Earnings per share (Unadj.) Rs-0.239.8 -0.5%  
Cash flow per share (Unadj.) Rs3.842.9 9.0%  
Dividends per share (Unadj.) Rs030.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs68.6236.9 29.0%  
Shares outstanding (eoy) m25.0084.70 29.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.19.1 55.4%   
Avg P/E ratio x-4,712.781.4 -5,788.2%  
P/CF ratio (eoy) x249.675.5 330.5%  
Price / Book Value ratio x14.013.7 102.3%  
Dividend payout %075.4 0.0%   
Avg Mkt Cap Rs m23,988274,216 8.7%   
No. of employees `0001.64.7 33.2%   
Total wages/salary Rs m1,6054,830 33.2%   
Avg. sales/employee Rs Th3,040.26,387.0 47.6%   
Avg. wages/employee Rs Th1,029.21,028.3 100.1%   
Avg. net profit/employee Rs Th-3.3717.1 -0.5%   
INCOME DATA
Net Sales Rs m4,74030,000 15.8%  
Other income Rs m92728 12.6%   
Total revenues Rs m4,83230,728 15.7%   
Gross profit Rs m-1304,190 -3.1%  
Depreciation Rs m101263 38.5%   
Interest Rs m00-   
Profit before tax Rs m-1394,655 -3.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m139457 30.4%   
Tax Rs m51,744 0.3%   
Profit after tax Rs m-53,368 -0.2%  
Gross profit margin %-2.714.0 -19.6%  
Effective tax rate %-3.737.5 -9.8%   
Net profit margin %-0.111.2 -1.0%  
BALANCE SHEET DATA
Current assets Rs m2,72616,742 16.3%   
Current liabilities Rs m2,4357,202 33.8%   
Net working cap to sales %6.131.8 19.3%  
Current ratio x1.12.3 48.2%  
Inventory Days Days7452 142.3%  
Debtors Days Days4121 196.1%  
Net fixed assets Rs m1,0358,635 12.0%   
Share capital Rs m50847 5.9%   
"Free" reserves Rs m94219,222 4.9%   
Net worth Rs m1,71620,069 8.6%   
Long term debt Rs m010 0.0%   
Total assets Rs m4,15630,038 13.8%  
Interest coverage xNMNM-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.11.0 114.2%   
Return on assets %-0.111.2 -1.1%  
Return on equity %-0.316.8 -1.8%  
Return on capital %025.5 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m375528 70.9%   
Fx outflow Rs m4707,193 6.5%   
Net fx Rs m-96-6,665 1.4%   
CASH FLOW
From Operations Rs m-82,360 -0.3%  
From Investments Rs m-1463,008 -4.8%  
From Financial Activity Rs m862-5,108 -16.9%  
Net Cashflow Rs m709260 272.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 0.3 10.2 2.9%  
FIIs % 15.7 23.8 66.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 15.4 59.1%  
Shareholders   12,856 102,036 12.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   STERLING BIOTECH  SANOFI INDIA  DR. DATSONS LABS  ORCHID PHARMA LTD  PFIZER  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Dull End to the Trading Day; Metal & Auto Stocks Fall(Closing)

Indian share markets continued to trade range-bound in the afternoon session amid mixed international markets. At the closing bell, the BSE Sensex closed higher by 27 points.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

When the Sherlock Holmes in Me Follows Super Investors...(The 5 Minute Wrapup)

Nov 11, 2017

This Super Investor has knack of spotting megatrends in India.

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

The Day Warren Buffett Lost All His Money(Smart Contrarian)

Nov 15, 2017

Buffett is still using the lessons he learnt that fateful day.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 23, 2017 03:35 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS